BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

23 related articles for article (PubMed ID: 38484558)

  • 1. Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1α to inhibit autophagy.
    Feng Z; Zhang S; Han Q; Chu T; Wang H; Yu L; Zhang W; Liu J; Liang W; Xue J; Wu X; Zhang C; Wang Y
    Phytomedicine; 2024 Jul; 129():155647. PubMed ID: 38703660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α).
    Zhang L; Wu H; Zhang Y; Xiao X; Chu F; Zhang L
    Bioengineered; 2022 Jan; 13(1):950-962. PubMed ID: 34969360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LINC00152 mediates CD8
    Ou J; Lei P; Yang Z; Yang M; Luo L; Mo H; Luo G; He J
    J Mol Histol; 2021 Jun; 52(3):611-620. PubMed ID: 33709190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
    Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
    J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
    Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S
    J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2 -induced doxorubicin resistance in breast cancer cells.
    Li Z; Zhu Q; Hu L; Chen H; Wu Z; Li D
    Cancer Sci; 2015 Aug; 106(8):1041-9. PubMed ID: 26079208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF-1α in colorectal carcinoma: review of the literature.
    Ioannou M; Paraskeva E; Baxevanidou K; Simos G; Papamichali R; Papacharalambous C; Samara M; Koukoulis G
    J BUON; 2015; 20(3):680-9. PubMed ID: 26214618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N
    Front Immunol; 2020; 11():976. PubMed ID: 32547545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas.
    Furlan D; Sahnane N; Carnevali I; Cerutti R; Uccella S; Bertolini V; Chiaravalli AM; Capella C
    Surg Oncol; 2007 Dec; 16 Suppl 1():S25-7. PubMed ID: 18023174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.
    Pan M; Wei X; Xiang X; Liu Y; Zhou Q; Yang W
    Clin Transl Oncol; 2023 Aug; 25(8):2306-2320. PubMed ID: 37076663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIF-1α Mediates Immunosuppression and Chemoresistance in Colorectal Cancer by Inhibiting CXCL9, -10 and -11.
    Su Y; Liu J; Tian Y; Dong H; Shi M; Zhang J; Li W; Huang Q; Xiang N; Wang C; Liu J; He L; Hu L; Haberman AM; Liu H; Yang X
    Biomed Pharmacother; 2024 Apr; 173():116427. PubMed ID: 38484558
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.